McKesson Corporation 10-Q Summary
Business Context and Reporting Period
This is a Quarterly Report (Form 10-Q) for McKesson Corporation for the quarter and six months ended September 30, 2006 (Fiscal Year 2007). McKesson operates in three primary segments: Pharmaceutical Solutions, Medical-Surgical Solutions, and Provider Technologies. The company is a large accelerated filer incorporated in Delaware.
Key Financial Metrics
| Metric | Quarter Ended Sep 30, 2006 | Six Months Ended Sep 30, 2006 |
|---|---|---|
| Revenues | $22,386 million | $45,701 million |
| Gross Profit | $1,024 million (4.57% margin) | $2,020 million (4.42% margin) |
| Operating Income | $306 million | $578 million |
| Net Income | $229 million | $413 million |
| Diluted EPS | $0.75 | $1.35 |
| Cash from Operations | N/A (Quarterly not provided) | $685 million |
| Cash and Equivalents | $2,254 million | $2,254 million |
| Total Debt | $984 million (Long-term $959M + Current $25M) | $984 million |
| Working Capital | $3,372 million | $3,372 million |
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 5% for the quarter and 9% for the six months compared to the prior year, driven primarily by the Pharmaceutical Solutions segment (95% of total revenue).
- Profitability: Net income increased 37% for the quarter and 22% for the six months. Diluted EPS rose 42% and 25%, respectively.
- Discontinued Operations: The company recorded a significant after-tax loss of $58 million for the quarter and six months due to the sale of its Acute Care business (classified as discontinued operations). This included a $79 million non-tax deductible goodwill write-off.
- Securities Litigation: A net pre-tax credit of $6 million was recorded for the quarter and six months, contrasting with a $52 million charge in the prior year period. Additionally, an $83 million tax credit was recorded due to an IRS ruling confirming the tax deductibility of the $960 million securities litigation settlement.
- Share-Based Compensation: Adoption of SFAS No. 123(R) resulted in increased operating expenses of $16 million for the quarter and $24 million for the six months compared to pro forma prior year figures.
Guidance, Outlook, and Risks
- Share Repurchases: The Board approved plans to repurchase up to $1 billion of common stock. As of September 30, 2006, $345 million remained available under these plans.
- Future Expenses: Management expects share-based compensation charges in 2007 to approximate $0.10 to $0.12 per diluted share, an increase of $0.02 per share from previous expectations.
- Restructuring: The company anticipates incurring approximately $5 million in restructuring charges in the latter part of 2007 related to the Medical-Surgical Solutions segment following the Acute Care divestiture.
- Risks: Key risks include the adverse resolution of pending shareholder litigation regarding the 1999 restatement, changes in government healthcare regulations, competition, and the impact of generic drug pricing. The company maintains a $1.3 billion revolving credit facility and a $700 million accounts receivable sales facility, with no amounts outstanding as of the reporting date.
Investor Verification Checklist
- Discontinued Operations Impact: Verify the extent to which the $58 million loss from discontinued operations (Acute Care sale) obscures core operating performance.
- Securities Litigation Reserve: Confirm the adequacy of the remaining $1,002 million accrual for securities litigation and the status of the $981 million held in escrow.
- Working Capital Fluctuations: Monitor cash flow from operations, which decreased significantly from $2,002 million in the prior year six-month period to $685 million, driven by inventory build-up and changes in receivables/payables timing.
- Share-Based Compensation: Assess the impact of the new SFAS 123(R) standard on future earnings, specifically the projected increase in per-share charges.
- Acquisition Integration: Review the integration progress and financial contribution of recent acquisitions, including D&K Healthcare Resources and Sterling Medical Services.